Related Experiment Videos
Pruritus and cholestasis: therapeutic options
1Bruce Hall Department of Gastroenterology, St Vincents Hospital, Darlinghurst, New South Wales, Australia.
Journal of Gastroenterology and Hepatology
|March 1, 1993
Summary
The causes of cholestasis-induced itching are complex, involving more than just bile salts, with central opiate pathways playing a key role. Current treatments include cholestyramine, rifampicin, and antihistamines, with opiate antagonists showing promise.
Area of Science:
- Hepatology
- Gastroenterology
- Dermatology
Background:
- The exact mechanisms causing pruritus (itching) in cholestasis are not fully understood.
- Bile salts are not the only substances triggering itching in cholestasis.
- Histaminergic pathways and central opiate receptor activity are implicated in cholestatic pruritus.
Purpose of the Study:
- To explore the pathogenesis of cholestatic pruritus.
- To review current and potential therapeutic strategies for cholestatic pruritus.
Main Methods:
- Review of existing literature on cholestatic pruritus.
- Analysis of the role of bile salts, histaminergic pathways, and opiate receptors.
- Summary of therapeutic options, including cholestyramine, rifampicin, antihistamines, opiate antagonists, ursodeoxycholic acid, methotrexate, EPO, and SAMe.
Main Results:
- Bile salts are insufficient to explain cholestatic pruritus.
- Central opiate pathways appear significantly involved.
- Cholestyramine is a first-line treatment; rifampicin and antihistamines are options for refractory cases.
- Opiate antagonists offer potential but require management of withdrawal symptoms.
- Ursodeoxycholic acid and methotrexate may offer disease-modifying benefits in specific conditions (PBC, PSC).
- EPO and SAMe are experimental and need further validation.
Conclusions:
- The pathogenesis of cholestatic pruritus is multifactorial, involving central opiate pathways.
- Current therapies include resins, rifampicin, and antihistamines, with opiate antagonists as a promising but challenging option.
- Further research is needed for agents like ursodeoxycholic acid, methotrexate, EPO, and SAMe to confirm their efficacy and potential disease-modifying effects.